脊髓小脑动症的改善 3 症状用心律疗法治疗:一个病例 视图
1Institute for Eurythmy Therapy, Alanus University of Arts and Social Sciences, Alfter, Germany.
Complementary medicine research
|July 30, 2023
概括
欧洲节律疗法可能会改善3型脊髓脑动症 (SCA3) 的症状. 一名患有SCA3的患者经历了睡眠障碍的减少,足部无敏和腿部,经过10次心律调节会话后.
科学领域:
- 神经学 神经学
- 补充医学是一种补充医学.
背景情况:
- 3型脊髓小脑动症 (SCA3) 是一种进展性神经退行性疾病.
- SCA3的特点是运动和非运动症状,包括睡眠障碍,感官缺陷和性.
研究的目的:
- 调查欧律疗法对管理SCA3症状的潜在益处.
- 评估eurythmy治疗对遗传确认SCA3.3患者的影响.
主要方法:
- 一名58岁的男性基因确诊SCA3接受了10次欧律疗法.
- 患者的症状严重程度被评估使用评估和评分缩症 (SARA) 的尺度.
- 治疗涉及基于内在图像的运动练习,没有改变药物或其他疗法.
主要成果:
- 患者的SARA得分从9分提高到7.5分.
- 在睡眠障碍,足部无敏和腿部方面报告了显著的改善.
- 在研究期间,没有实施其他疗法或药物改变.
结论:
- 欧律疗法对3型脊髓大脑动症的关键症状产生了积极的影响.
- 这一案例表明,欧律疗法是SCA3症状管理的潜在补充方法.
- 需要进一步的研究,以探索欧律律疗法在较大的SCA3队列中的疗效.
相关概念视频
01:24Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299
01:20Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K